Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 12,241 matching trials from the live ClinicalTrials.gov search.
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Conditions
Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
Procedure · Genetic · Other
Lead sponsor
National Tuberous Sclerosis Association
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
24
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries

NCT00495495
Conditions
Dental Caries
Interventions
Ozone treatment, Placebo treatment
Device
Lead sponsor
Indiana University
Other
Eligibility
10 Years to 40 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Buffalo, New York
Conditions
Chronic Kidney Disease
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Edgewater, Florida • Chicago, Illinois • Saint Paul, Minnesota + 2 more
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Eon™ FR Clinical Study Protocol 1064

NCT03898830
Conditions
Fat Disorder
Interventions
eon™ FR 1064 nm device
Device
Lead sponsor
Dominion Aesthetic Technologies, Inc.
Industry
Eligibility
21 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Altamonte Springs, Florida • Miami, Florida
Conditions
Multiple Myeloma
Interventions
Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw
Diagnostic Test · Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Conditions
Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases
Interventions
Harvesting and Implantation of SVF
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aventura, Florida
Completed No phase listed Observational

Tempus Pro Monitor Registry

NCT05587764
Conditions
Sudden Cardiac Arrest, Emergency Care
Interventions
Standard of Care
Diagnostic Test
Lead sponsor
Heartstream US LLC
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission, Adult Erythroleukemia (M6a), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, total-body irradiation, fludarabine phosphate, busulfan, allogeneic hematopoietic stem cell transplantation
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
39
States / cities
Berkeley, California • Duarte, California • La Jolla, California + 30 more
Conditions
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Interventions
GRN1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Active, not recruiting Phase 1 Interventional Results available

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567
Conditions
Prostate Cancer
Interventions
Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg, Fractionated Dose of 225Ac-J591 at 55 KBq/kg, Fractionated Dose of 225Ac-J591 at 60 KBq/kg, Fractionated Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL), Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL), 68Ga-PSMA-HBED-CC injection
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Conditions
Basal Cell Nevus Syndrome, Gorlin's Syndrome
Interventions
Vismodegib, Aminolevulinic acid %20 topical solution
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Oakland, California • New York, New York
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Conditions
Depressive Disorder, Major
Interventions
Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more